IP Library Granted Patent US 11,642,396
Granted Patent B2
US 11,642,396 · App. 14/913,562 · Granted May 9, 2023

Method of reducing antigenic drift or reassortment of viruses in a host animal using α interferon

Inventors: William A. Carter (Ocala, FL); David R. Strayer (Ocala, FL)
Assignee: AIM ImmunoTech Inc.
A61K38/212A61K31/713C12Q1/701
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,642,396
App. No.
14/913,562
Granted
May 9, 2023
Kind
B2
Abstract

This disclosures relates to methods of preventing or reducing antigenic drift, viral reassortment and symptoms of wild-type and mutant influenza viruses in a host animal by determining if a host animal has been exposed to or infected by an avian influenza virus, and administering to the exposed host animal α-interferon.

Claims (8)

1. A method for reducing antigenic drift or viral reassortment in a human comprising determining if the human has been exposed to or infected by an avian influenza virus, and administering to the exposed or the infected human α-interferon;

wherein the α-interferon comprises seven species of α-interferon comprises α-interferon species α2, α4, α7, α8, α10, α16 and α17;

wherein the α-interferon is administered intravenously, subcutaneously, intramuscularly, or intranasally.

2. The method of claim 1 wherein the avian influenza virus is selected from the group consisting of NA-292R H7N9, NA-292K H7N9 or a combination thereof.

3. The method of claim 1 wherein the avian influenza virus is a combination of NA-292R H7N9, NA-292K H7N9 and at least one more avian influenza virus.

4. The method of claim 1 wherein the α-interferon species were purified as a mixture of at least seven species of α-interferon produced by human white blood cells.

5. The method of claim 1 , wherein the α-interferon administered is within a concentration of at least within 1,000 IU/ml to 10,000 IU/ml.

6. The method of claim 1 , wherein the α-interferon administered is within 1,000 IU to 10,000,000 IU per dose.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2020
From: CARTER, WILLIAM A.; STRAYER, DAVID R.
To: HEMISPHERX BIOPHARMA, INC.
Reel/Frame 052254/0858 →
CHANGE OF NAME Recorded Mar 30, 2020
From: HEMISPHERX BIOPHARMA, INC.
To: AIM IMMUNOTECH INC.
Reel/Frame 052254/0889 →
Continuity (2)
Provisional Application 61868292 · Aug 21, 2013
Related Publication 20160199449A1 · Jul 14, 2016